InnerworldEagle Pharmaceuticals Inc. has agreed to pay investors $9.5 million to settle class claims that it “stuffed” its drug distribution channels to boost its reported revenue
Eagle Pharmaceuticals Inc. has agreed to pay investors $9.5 million to settle class claims that it “stuffed” its drug distribution channels to boost its reported revenue
